Filing Analysis
Exagen Inc. filed an 8-K to report its financial results for the three and six months ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings performance.
📋 Key Facts
- Reported financial results for the three and six months ended June 30, 2026.
- Filing date: August 4, 2026.
- The report includes Exhibit 99.1 containing a press release regarding the results.
Exagen Inc. reported the final voting results from its 2026 annual meeting of stockholders held on June 9, 2026. Stockholders elected two Class I directors, ratified the appointment of BDO USA, P.C. as the independent auditor, and approved executive compensation.
📋 Key Facts
- Election of Class I directors Tina S. Nova, Ph.D. and Scott Kahn, Ph.D. for three-year terms expiring in 2029.
- Ratification of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Advisory approval of named executive officer compensation.
- Significant broker non-votes were present in Proposal 1 (approx 17.3M total) and Proposal 3 (approx 8.6M).
Exagen Inc. reported its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results reported for the three months ended March 31, 2026
- Filing date and report date are both May 11, 2026
- Information was furnished under Item 2.02 (Results of Operations and Financial Condition)
- The report was signed by Jeffrey G. Black, Chief Financial Officer
On April 17, 2026, Ana Hooker resigned from Exagen Inc.'s Board of Directors and its committees. The company subsequently reduced its board size from eight to seven members and reconstituted its standing committees.
📋 Key Facts
- Ana Hooker resigned as a director effective April 17, 2026.
- Ms. Hooker served as the chair of the Nominating and Corporate Governance Committee and was a member of the Audit Committee.
- The resignation was not due to any disagreement with the company's operations, policies, or practices.
- The Board of Directors' size was reduced from eight to seven members following the resignation.
- The company announced the new composition of the Audit, Compensation, and Nominating and Corporate Governance committees.
Exagen Inc. reported its financial results for the fourth quarter and fiscal year ended December 31, 2025, via a press release furnished with the SEC.
📋 Key Facts
- Financial results for Q4 and FY 2025 reported on March 10, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the full press release
Exagen Inc. announced preliminary unaudited financial results for the three months and fiscal year ended December 31, 2025. The company noted that these figures are subject to change as final closing procedures are completed.
🚩 Red Flags
- Preliminary nature of data: The company explicitly warns that final results may vary due to incomplete closing procedures.
📋 Key Facts
- Report date: January 11, 2026
- Reporting period: Three months and full year ended December 31, 2025
- The financial information provided is preliminary and unaudited
- Final results may vary from the preliminary figures presented in the press release
Exagen Inc. filed an 8-K to announce its financial results for the three and nine months ended September 30, 2025. The filing serves as a formal notice that earnings data was released via press release.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2025.
- Filing date: November 4, 2025.
- The report includes results of operations and financial condition as per Item 2.02.
Exagen Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2025. The filing serves as a formal notification that earnings data has been released via press release.
📋 Key Facts
- Reported financial results for the three and six months ended June 30, 2025.
- Filing date: July 29, 2025.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Exagen Inc. announced the appointment of Charles S. McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann will serve as a Class III director and join the Compensation and Nominating Committees, increasing the total board size from seven to eight members.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Effective date of appointment: July 17, 2025.
- Charles S. McKhann appointed as Class III director.
- Board size increased from 7 to 8 members.
- Mr. McKhann appointed to the Compensation Committee and Nominating Committee.
- Compensation includes up to 7,500 RSUs vesting over four years and an option for 9,000 shares contingent on annual meetings.
- McKhann has a background as CEO/President at Silk Road Medical (acquired by Boston Scientific) and Apollo Endosurgery (acquired by Boston Scientific).
Exagen Inc. held its 2025 annual meeting of stockholders on June 10, 2025. The filing reports the final voting results for director elections, auditor ratification, and advisory votes on executive compensation.
📋 Key Facts
- Annual Meeting held on June 10, 2025.
- Two Class III directors elected: John Aballi (8,593,115 votes for) and Bruce C. Robertson, Ph.D. (5,656,283 votes for).
- BDO USA, P.C. was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Stockholders approved advisory compensation of named executive officers.
- Stockholders voted on the frequency of future 'Say-on-Pay' votes; the company will hold these annually until the next required vote.
Exagen Inc. closed a public offering of common stock on May 9, 2025, resulting in approximately $18.6 million in net proceeds. The offering included the full exercise of the underwriters' option to purchase additional shares.
🚩 Red Flags
- Equity dilution: The issuance of over 3.8 million new shares will dilute existing shareholders.
📋 Key Facts
- Closed public offering of 3,350,000 shares of common stock.
- Offering price was $5.25 per share.
- Underwriter exercised option in full for an additional 502,500 shares on May 8, 2025.
- Total net proceeds (after discounts and expenses) are approximately $18.6 million.
Exagen Inc. entered into an underwriting agreement with Canaccord Genuity LLC to issue 3,350,000 shares of common stock at $5.25 per share. The offering is expected to close on May 9, 2025, providing approximately $16.2 million in net proceeds for working capital and potential strategic investments.
🚩 Red Flags
- Equity Dilution: Issuance of 3.35M+ new shares will dilute existing shareholders.
📋 Key Facts
- Underwriter: Canaccord Genuity LLC
- Total Firm Shares: 3,350,000 shares of common stock
- Offering Price: $5.25 per share
- Option Shares: Up to 502,500 additional shares (30-day option)
- Expected Net Proceeds: Approximately $16.2 million after expenses
- Use of Proceeds: Working capital, general corporate purposes, and potential acquisitions/in-licensing
- Closing Date: Expected May 9, 2025
Exagen Inc. filed an 8-K to report its financial results for the first quarter ended March 31, 2025. The filing serves as a formal notification of the earnings release issued via press release.
📋 Key Facts
- Reporting period: Three months ended March 31, 2025.
- Report date: May 5, 2025.
- The company furnished Exhibit 99.1 containing the earnings press release.
Exagen Inc. entered into a $75 million senior secured delayed draw term loan facility with Perceptive Credit Holdings IV, LP, which includes an immediate $25 million Tranche A funding. The agreement is heavily structured with significant equity warrants and performance-based tranches.
🚩 Red Flags
- High-cost debt: The 7% margin over SOFR is significant for a micro-cap/small-cap company.
- Equity dilution: Issuance of warrants for up to 1.15 million shares represents significant potential dilution.
- Restrictive covenants: Includes revenue milestones and minimum unrestricted cash requirements ($3.0M) that could trigger default.
- Default penalty: Interest rate increases by an additional 4% (to 11% + SOFR) upon Event of Default.
📋 Key Facts
- Total facility amount: up to $75.0 million via a senior secured delayed draw term loan.
- Immediate funding (Tranche A): $25.0 million, resulting in net proceeds of approximately $22.8 million.
- Maturity date: April 25, 2030, with an interest-only period and full principal due at maturity.
- Interest rate: Term SOFR + 7% (with a 4% penalty increase upon Event of Default).
- Security: First lien perfected security interest on substantially all existing and future assets.
- Warrants issued: Up to 1,150,000 shares of common stock with various vesting schedules tied to borrowing tranches.
Exagen Inc. filed an 8-K to report its financial results for the quarter and fiscal year ended December 31, 2024. The filing serves as a formal announcement of quarterly earnings performance.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2024.
- Filing date: March 11, 2025.
- The report includes the company's press release as Exhibit 99.1.
Exagen Inc. announced preliminary unaudited financial results and operating information for the three months and fiscal year ended December 31, 2024. The company noted that these figures are subject to change as final closing procedures are completed.
🚩 Red Flags
- Preliminary nature of data: Results are subject to change as closing procedures are finalized
📋 Key Facts
- Report date: January 12, 2025
- Reporting period: Three months and fiscal year ended December 31, 2024
- The financial information provided is preliminary and unaudited
- Final results may vary from the preliminary figures presented in the press release
- BDO USA, P.C. has not audited or reviewed the preliminary information
Exagen Inc. filed an 8-K to report its financial results for the three and nine months ended September 30, 2024. The filing serves as a formal announcement of quarterly earnings performance.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2024.
- Filing date: November 12, 2024.
- The report includes results of operations and financial condition via a press release (Exhibit 99.1).
Exagen Inc. filed an 8-K to report its financial results for the three and six months ended June 30, 2024. The filing serves as a formal announcement of quarterly earnings performance.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2024.
- Filing date: August 5, 2024.
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
Exagen Inc. is amending a previous 8-K to correct clerical errors regarding the termination of CFO Kamal Adawi and has announced a leadership transition in the finance department. Jeffrey Black has been appointed as the new CFO effective September 1, 2024, while John Aballi will serve as Interim CFO until then.
🚩 Red Flags
- CFO turnover: The company has experienced a rapid transition with the departure of Kamal Adawi and the appointment of an interim CFO before the permanent successor arrives.
- Amendment to previous filing: The need for an 8-K/A to correct officer identity and effective dates can sometimes indicate internal administrative lapses.
📋 Key Facts
- Jeffrey Black appointed as CFO and principal financial officer, effective September 1, 2024.
- Jeffrey Black's compensation includes a $460,000 base salary, a $125,000 signing bonus, and up to 225,000 RSUs vesting over four years.
- John Aballi appointed as Interim CFO effective August 1, 2024, following the departure of Kamal Adawi.
- Kamal Adawi's termination was effective August 1, 2024; he is entitled to severance benefits under the company's Severance Plan subject to a release of claims.
- The filing is an amendment (8-K/A) to correct signature dates and officer identities from the original August 2, 2024 filing.
Exagen Inc. announced a leadership transition in its finance department, including the appointment of Jeffrey Black as new CFO effective September 1, 2024, and the departure of Kamal Adawi. John Aballi will serve as Interim CFO until Mr. Black's arrival.
🚩 Red Flags
- Sudden departure of the CFO and Corporate Secretary.
- Need for an interim CFO suggests an unplanned or rapid transition.
📋 Key Facts
- Jeffrey Black appointed as Chief Financial Officer, effective September 1, 2024.
- Kamal Adawi departed from his role as CFO and Corporate Secretary, effective July 31, 2024.
- John Aballi appointed as Interim CFO and principal financial officer effective July 31, 2024.
- Jeffrey Black's compensation includes a $460,000 base salary, a $125,000 signing bonus, and up to 225,000 restricted stock units (RSUs) vesting over four years.
- Kamal Adawi is entitled to severance benefits under the Company's Severance Plan subject to a release of claims.
Exagen Inc. held its 2024 annual meeting of stockholders on June 10, 2024. The filing reports the final voting results for the election of three Class II directors and the ratification of BDO USA, P.C. as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 10, 2024.
- Three Class II directors elected: Ana Hooker, Paul Kim, and Frank Stokes for three-year terms expiring in 2027.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Exagen Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice that earnings data is being released via press release.
📋 Key Facts
- Reported financial results for the three months ended March 31, 2024.
- Filing date: May 13, 2024.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Exagen Inc. announced the resignation of three board members (Brian Birk, Wendy Johnson, and Ebetual Pallares) effective June 10, 2024. To fill one vacancy, the company appointed Dr. Scott D. Kahn to the Board and its Compensation and Nominating committees.
🚩 Red Flags
- Significant reduction in board size (from 9 to 7 members) may indicate a period of transition or restructuring.
- Simultaneous departure of three directors can sometimes signal internal shifts, though the filing explicitly denies disagreement.
📋 Key Facts
- Three directors—Brian Birk, Wendy Johnson, and Ebetual Pallares, Ph.D.—will resign effective June 10, 2024.
- The resignations are not due to any disagreement with the Company's operations, policies, or practices.
- Dr. Scott D. Kahn, Ph.D., has been appointed as a Class I director, effective June 10, 2024.
- Board size will decrease from nine members to seven members following these changes.
- Dr. Kahn's compensation includes options for 15,000 shares (3-year vesting) and 9,000 shares (1-year or annual meeting vesting).
- Dr. Kahn brings significant experience, including serving as CIO at Illumina, Inc.
Exagen Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023. The filing serves as a formal announcement of earnings rather than a specific material event like a merger or leadership change.
📋 Key Facts
- Reported financial results for the quarter and year ended December 31, 2023.
- Filing date: March 18, 2024.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Exagen Inc. released preliminary unaudited financial information and results of operations for the fiscal year ended December 31, 2023. The filing serves as a placeholder to furnish management's preliminary data via an attached press release.
📋 Key Facts
- Report date: January 7, 2024
- Reporting period: Year ended December 31, 2023
- Nature of information: Preliminary and unaudited financial results
- Auditor status: BDO USA, P.C. has not audited or reviewed the provided preliminary data.